Search research articles
Contact Us
Filters
Showing results (131-140 of 144) with videos related to
Page
of 15
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2021
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study
Paolo Denti, Roeland E Wasmann, Annelies van Rie, et al.
Plos Medicine
|
November 22, 2013
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa
Michael Schomaker, Matthias Egger, James Ndirangu, et al.
Lancet (London, England)
|
November 12, 2013
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial
Mark F Cotton, Avy Violari, Kennedy Otwombe, et al.
The Lancet. HIV
|
October 11, 2025
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial
Adrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 10, 2020
Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2-Related Illness in Children: Hospital Experience in Cape Town, South Africa
Marieke M van der Zalm, Juanita Lishman, Lilly M Verhagen, et al.
The Pediatric Infectious Disease Journal
|
March 19, 2019
What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies
Gabriela Patten, Michael Schomaker, Mary-Ann Davies, et al.
The Lancet. HIV
|
August 14, 2025
Research gaps for children who are HIV-exposed but uninfected: outcomes of a research prioritisation workshop
Catherine J Wedderburn, Ceri Evans, Elaine J Abrams, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
June 20, 2026
Evaluating Mucosal and Systemic Immunity in an Observational Cohort of South African Children Hospitalised with Acute Respiratory Tract Infections
Geert van Weelden, Helena Rabie, Andrew Redfern, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Helena Rabie, Dwight E Yin, Shawn Ward, et al.
The Lancet. HIV
|
August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study
Kristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 144) with videos related to
Sort By:
Page
of 15
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2021
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study
Paolo Denti, Roeland E Wasmann, Annelies van Rie, et al.
Plos Medicine
|
November 22, 2013
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa
Michael Schomaker, Matthias Egger, James Ndirangu, et al.
Lancet (London, England)
|
November 12, 2013
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial
Mark F Cotton, Avy Violari, Kennedy Otwombe, et al.
The Lancet. HIV
|
October 11, 2025
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial
Adrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 10, 2020
Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2-Related Illness in Children: Hospital Experience in Cape Town, South Africa
Marieke M van der Zalm, Juanita Lishman, Lilly M Verhagen, et al.
The Pediatric Infectious Disease Journal
|
March 19, 2019
What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies
Gabriela Patten, Michael Schomaker, Mary-Ann Davies, et al.
The Lancet. HIV
|
August 14, 2025
Research gaps for children who are HIV-exposed but uninfected: outcomes of a research prioritisation workshop
Catherine J Wedderburn, Ceri Evans, Elaine J Abrams, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
June 20, 2026
Evaluating Mucosal and Systemic Immunity in an Observational Cohort of South African Children Hospitalised with Acute Respiratory Tract Infections
Geert van Weelden, Helena Rabie, Andrew Redfern, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Helena Rabie, Dwight E Yin, Shawn Ward, et al.
The Lancet. HIV
|
August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study
Kristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
Page
of 15